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Diagnosis of Mediastinal Adenopathy—Real-Time
Endobronchial Ultrasound Guided Needle Aspiration
versus Mediastinoscopy
Armin Ernst, MD, FCCP,*† Devanand Anantham, MRCP,‡ Ralf Eberhardt, MD,†
Mark Krasnik, MD,§ and Felix J. F. Herth, MD, FCCP†
Background: Real-time endobronchial ultrasound has increased the
accuracy of conventional transbronchial needle aspiration biopsy in
sampling mediastinal lymph nodes. Nevertheless, direct compari-
sons with mediastinoscopy are not available to determine the role of
endobronchial ultrasound in pathologic staging.
Objectives: To compare the diagnostic yield of endobronchial
ultrasound against cervical mediastinoscopy in the diagnosis and
staging of radiologically enlarged mediastinal lymph nodes stations
accessible by both modalities in patients with suspected nonsmall
cell lung cancer.
Methods: Prospective, crossover trial with surgical lymph node
dissection used as the accepted standard. Biopsy results of paratra-
cheal and subcarinal lymph nodes were compared.
Results: Sixty-six patients with a mean age 60  10 years were
studied. The prevalence of malignancy was 89% (59/66 cases).
Endobronchial ultrasound had a higher overall diagnostic yield
(91%) compared with mediastinoscopy (78%; p  0.007) in the per
lymph node analysis. There was disagreement in the yield between
the two procedures in the subcarinal lymph nodes (24%; p 0.011).
There were no significant differences in the yield at other lymph
node stations. The sensitivity, specificity, and negative predictive
value of endobronchial ultrasound were 87, 100, and 78%, respec-
tively. The sensitivity, specificity, and negative predictive value of
mediastinoscopy were 68, 100, and 59%, respectively. No signifi-
cant differences were found between endobronchial ultrasound
(93%) and mediastinoscopy (82%; p  0.083) in determining true
pathologic N stage (per patient analysis).
Conclusions: In suspected nonsmall cell lung cancer, endobronchial
ultrasound may be preferred in the histologic sampling of paratra-
cheal and subcarinal mediastinal adenopathy because the diagnostic
yield can surpass mediastinoscopy.
Key Words: Endobronchial ultrasound, Cervical mediastinoscopy,
Nonsmall cell lung cancer, Transbronchial needle aspiration, Medi-
astinal lymph nodes.
(J Thorac Oncol. 2008;3: 577–582)
Accurate staging of the mediastinum is essential to evaluateprognosis in nonsmall cell lung cancer and to devise an
appropriate treatment plan. The poor sensitivity and specific-
ity of noninvasive radiologic techniques make histologic
staging indispensable in patients who are potential candidates
for surgical resection.1,2 The overall sensitivity of transbron-
chial needle aspiration (TBNA) in invasive staging is 78%
with a range of 14 to 100%.2 Endobronchial ultrasound (EBUS)
with a radial probe has an improved TBNA diagnostic yield of
71 to 85%.3–7 Real-time EBUS with a linear probe has pushed
the positive yields further into the 86 to 100% range.8–16 The
two components of successful diagnostic yield are true positives
from a definite histologic result and true negatives that either
need further confirmatory tests or adequate clinical follow-up.
The ability to obtain a definitive histologic diagnosis through
real-time EBUS-TBNA ranges from 24 to 94% and is largely
dependent on the prevalence of malignancy in the study
population.9–16 This has resulted in doubts over the negative
predictive value of EBUS-TBNA results. The recommenda-
tions stating that negative conventional TBNA results should
be verified with a mediastinoscopy may therefore also hold
true for real-time EBUS-TBNA.2
Although mediastinoscopy is regarded as the accepted
standard in the diagnosis of pathologic mediastinal lymph
nodes, the reported sensitivity is 78% with a range of 40 to
92%.2 Standard cervical mediastinoscopy has access limited
to paratracheal (station 2 and 4) and subcarinal (station 7)
lymph nodes. No direct evaluation has been made with other
invasive staging modalities and historical comparisons have
selection biases based on differing lymph node sizes, lymph
node stations, locally available expertise and risks of the
staging modality used. The specificity of mediastinoscopy is
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reported to be 100% but this has also never been confirmed
against surgical lymph node dissection.2
A prospective, crossover trial was conducted to com-
pare the diagnostic yields of real-time EBUS-TBNA against
cervical mediastinoscopy in patients with mediastinal ade-
nopathy and suspected nonsmall cell lung cancer. Systematic
lymph node dissection during surgical tumor resection was
used as our reference accepted standard to address the issue
of specificity.
METHODS
Consecutive subjects who had clinically suspected non-
small cell lung cancer were enrolled between January 2005
and July 2006. Clinical suspicion was based on age, symp-
toms, and risk factors such as smoking history and computed
tomography (CT) characteristics. Inclusion criteria required
technically resectable pulmonary lesions in patients fit for
operation with no clinical/radiologic evidence of T4 disease
or distant metastases. Positron emission tomography (PET) was
not used and histology was unconfirmed at time of enrollment.
Therefore, confirmation of diagnosis and staging proceeded
concurrently. Mediastinal adenopathy (10 mm) on CT had to
be confined to lymph node stations 2, 4 or 7 to qualify for
inclusion. Patients with lymphadenopathy at other mediastinal
lymph node stations were excluded because these lymph nodes
were inaccessible by either standard cervical mediastinoscopy or
EBUS. The Institutional Review Boards of the participating
centers approved the data collection and analysis.
Mediastinoscopy
Cervical mediastinoscopy was performed on all pa-
tients and was used as the standard of care in making
treatment decisions such as operation. Lymph node sampling
of all station 2, 4, and 7 nodes was done.
Real-Time EBUS-TBNA
EBUS evaluation was incorporated into the preoperative
airway inspection of the patients. EBUS was performed either as
separate procedure under moderate sedation and within 1 week
before mediastinoscopy or concurrently at the time of medisti-
noscopy under general anesthesia. Only pathologically enlarged
lymph nodes identified on CT scans were biopsied.
After airway examination with conventional bronchos-
copy, EBUS-TBNA was performed using the real-time ultra-
sound biopsy bronchoscope (XBF-UC260F-OL8; Olympus
Ltd, Tokyo, Japan). A 7.5 Hz linear ultrasound transducer
with a maximum penetration of 50 mm is linked to the EU-60
processor (Olympus Ltd, Tokyo, Japan). TBNA biopsies
were performed using a dedicated 22-gauge needle (XNA-
202, Olympus Ltd, Tokyo, Japan; Figure 1).
Lymph nodes were identified by slow withdrawal and
rotation of the ultrasound transducer. Intervening vessels
were avoided by using the integrated Doppler function. The
jabbing method was used to obtain biopsies and two passes
were made at each lymph node station. The aspirate was
placed on four glass slides, air-dried, and stained. No rapid
on-site cytologic evaluation was used. If multiple lymph node
stations were biopsied, a different needle was used for each
station after flushing the working channel with normal saline.
Surgery
Patients who had negative mediastinal evaluations by
both EBUS-TBNA and mediastinoscopy underwent surgical
resection and systematic lymph node dissections. Nonsmall
cell lung cancer cases confirmed by either procedure were
also offered operation in instances of limited stage 3A disease
with single station N2 disease and no evidence of extracap-
sular spread on mediastinoscopy on protocol.
End-Points
Primary outcome was comparative diagnostic yields of
EBUS-TBNA and cervical mediastinoscopy in the evaluation
of lymph nodes that were enlarged on CT scans. Diagnostic
yields incorporated both true positive and true negative re-
sults. The ability of either procedure to establish a specific
histologic diagnosis was a secondary objective. Agreement
between EBUS-TBNA and mediastinoscopy was also evalu-
ated. Safety was assessed by recording all complications.
Data Analysis
Statistical analyses were performed using SAS statisti-
cal software (SAS Institute, Cary, North Carolina, USA).
Continuous variables are expressed using mean and standard
deviation. Categorical variables are summarized as counts
and percents. Comparisons of continuous variables were done
with Student’s t tests. 2 test or Fisher’s exact test, as
appropriate was used for comparing proportions. McNemar’s
test was used for evaluating agreement between the two
procedures. Generalized estimating equations were used for
multivariate analysis of yield using the covariates of lymph
node station and histology. A two-tailed p value of 0.05
indicated statistical significance.
RESULTS
Eighty-five patients were identified as possible subjects
after review by the multidisciplinary tumor boards. Nineteen
patients could not be enrolled, as they either refused consent
(n 17) of were deemed unfit for anesthesia (n 2). Sixty-six
patients met inclusion criteria and were enrolled and 120 en-
larged mediastinal lymph nodes (mean lymph nodes per patient:
1.8  0.1 with a range of 1–4) were biopsied by both EBUS-
FIGURE 1. The ultrasound image shows the clear delinea-
tion of a small lymph node (n) during endobronchial ultra-
sound guided TBNA. On the left the same lymph node after
resection. The puncture mark is visible as a red mark on the
left corner of the node.
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TBNA and mediastinoscopy. Operation was performed by eight
different surgeons and EBUS TBNA was performed by three
different endoscopists. The patients’ mean age was 60  10
years and 29/66 (44%) were females. The prevalence of malig-
nancy was 59/66 (89%). Of these 59 patients, there were 57
cases of nonsmall cell lung cancer, one case of small cell lung
cancer and one case of lymphoma. There were seven patients
with benign disease: three cases of sarcoidosis, two pulmonary
tuberculosis, and two nonspecific inflammation.
A definitive histologic diagnosis was established by
either EBUS-TBNA or mediastinoscopy in 49 (49/66; 74%)
patients before operation (Figure 2). Operation was per-
formed for either therapeutic or diagnostic indications in 61
(61/66; 92%) patients. Therefore, the sensitivity and speci-
ficity of EBUS-TBNA and mediastinoscopy was compared
against operation as the accepted standard in 112 (112/120;
93%) lymph nodes. Five patients who did not undergo oper-
ation (three sarcoidosis, one lymphoma, and one tuberculosis)
had eight (8/120; 7%) enlarged mediastinal lymph nodes.
Definitive histology was available on all eight lymph nodes
from either EBUS-TBNA or mediastinoscopy and was con-
sidered the accepted standard in these patients.
Diagnostic Yield
The 120 lymph nodes that were sampled had a mean
size of 15  2.6 mm; range: 10 to 21 mm. The diagnostic
yield in a per lymph node analysis of EBUS-TBNA (109/120;
91%) was higher than the yield of mediastinoscopy (94/120;
FIGURE 2. Patient flow and final histo-
logic diagnosis.
TABLE 1. Diagnostic Yield of EBUS-TBNA and Mediastinoscopy in the Evaluation of
Mediastinal Lymph Nodes
Lymph Node Size in mm:
Mean  SD (Range) EBUS Yield (%)
Mediastinoscopy
Yield (%) pa
All lymph nodes 15  2.6 (10–21) 109/120 (91) 94/120 (78) 0.007
Lymph node station
2 all 16  3.1 (10–21) 24/25 (96) 22/25 (88) 0.30
2 right 18  1.6 (14–20) 12/13 (92) 11/13 (85) 0.99
2 left 14  3.6 (10–21) 12/12 (100) 11/12 (92) 0.99
4 all 15  2.6 (10–19) 45/54 (83) 40/54 (74) 0.24
4 right 15  2.6 (10–19) 29/34 (85) 24/34 (71) 0.14
4 left 15  2.6 (10–19) 16/20 (80) 16/20 (80) 0.99
7 15  2.4 (10–19) 40/41 (98) 32/41 (78) 0.007
Pathology
Malignant 16  2.7 (10–21) 64/74 (86) 49/74 (66) 0.004
Benign 15  2.5 (10–21) 45/46 (98) 45/46 (98) 0.99
a 2 test.
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78%; p  0.007). A higher accuracy of EBUS-TBNA in the
subcarinal lymph node station was observed (Table 1). The
diagnostic rates from the paratracheal lymph node stations
were not different between the two procedures. The lymph
node sizes in the various lymph node stations were similar
and there was no significant difference in size between
malignant (16  2.7 mm) and benign lymph nodes (15  2.5
mm; p  0.14). The diagnostic yield of EBUS-TBNA was
also higher among the malignant lymph nodes (86 versus
66%; p  0.004).
In multivariate analysis, real-time EBUS-TBNA had a
higher diagnostic yield than mediastinoscopy (p  0.005).
However, there was no statistical significant interaction be-
tween lymph node station and malignant/benign histology
(p  0.395).
The sensitivity of real-time EBUS-TBNA was 71/82
(87%) and specificity was 38/38 (100%). The prevalence of
malignancy in all the lymph nodes biopsied was 74/120
(62%) and the negative predictive value of EBUS-TBNA was
38/49 (78%). The sensitivity, specificity, and negative pre-
dictive value of mediastinoscopy was 56/82 (68%), 38/38
(100%), and 38/64 (59%), respectively.
In a per patient analysis, the overall diagnostic yield of
EBUS-TBNA was 59/66 (89%) and the yield of mediastinos-
copy was 52/66 (79%; p  0.1). In the 57 patients with
nonsmall cell lung cancer, the correct pathologic N stage was
predicted in 53/57 (93%) with EBUS-TBNA and in 47/57
(82%) with mediastinoscopy (p  0.083).
In obtaining a definite histologic diagnosis, there was
trend towards a better result with EBUS-TBNA (59%) com-
pared with mediastinoscopy (47%) but this did not reach
statistical significance (p  0.05). This trend towards an
improved diagnostic result was also seen in the subcarinal
lymph node station (Table 2).
The overall agreement between the diagnostic yields of
EBUS-TBNA and mediastinoscopy was 78%. Significant
TABLE 2. Definite Histological Diagnosis from EBUS-TBNA and Mediastinoscopy in the
Evaluation of Mediastinal Lymph Nodes
Lymph Node Size in mm:





All lymph nodes 15  2.6 (10–21) 71/120 (59) 56/120 (47) 0.05
Lymph node station
2 all 16  3.1 (10–21) 13/25 (52) 11/25 (44) 0.57
2 right 18  1.6 (14–20) 8/13 (62) 7/13 (54) 0.69
2 left 14  3.6 (10–21) 5/12 (42) 4/12 (33) 0.99
4 all 15  2.6 (10–19) 32/54 (59) 27/54 (50) 0.33
4 right 15  2.6 (10–19) 20/34 (59) 15/34 (44) 0.23
4 left 15  2.6 (10–19) 12/20 (60) 12/20 (60) 0.99
7 15  2.4 (10–19) 26/41 (63) 18/41 (44) 0.08
Pathology
Malignant 16  2.7 (10–21) 64/74 (86) 49/74 (66) 0.004
Benign 15  2.5 (10–21) 7/46 (15) 7/46 (15) 0.99
a 2 test.
TABLE 3. Agreement in Definite Histological Diagnosis between EBUS-TBNA and Mediastinoscopy in




All lymph nodes 93/120 (78) 21/120 (18) 6/120 (5) 0.004b
Lymph node station
2 all 23/25 (92) 2/25 (8) 0/25 (0) 0.16
2 right 12/13 (92) 1/13 (8) 0/13 (0) 0.32
2 left 11/12 (92) 1/12 (8) 0/12 (0) 0.32
4 all 39/54 (72) 10/54 (19) 5/54 (9) 0.20
4 right 25/34 (74) 7/34 (21) 2/34 (6) 0.10
4 left 14/20 (70) 3/20 (15) 3/20 (15) 1.00
7 31/41 (76) 9/41 (22) 1/41 (2) 0.011
Pathology
Malignant 47/74 (64) 21/74 (28) 6/74 (8) 0.004
Benign 46/46 (100) 0/46 (0) 0/46 (0) —
a McNemar’s test.
MED, mediastinoscopy.
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disagreement between the two procedures was found in the
subcarinal station and in lymph nodes with evidence of
malignant metastases (Table 3). Analysis of the cases where
there was disagreement revealed that there were more cases
when EBUS-TBNA resulted in definitive diagnosis and me-
diastinoscopy was negative (18%) compared with when me-
diastinoscopy yielded a positive diagnosis and EBUS-TBNA
was negative (5%; p  0.004).
The overall diagnostic yield of combining EBUS-
TBNA and mediastinoscopy was 115/120 (96%). This was
not significantly higher than the 91% yield of EBUS alone
(p  0.20). The five nondiagnostic lymph node biopsies by
both EBUS-TBNA and medaistinoscopy occurred in four
patients. In two patients (Stations 4R and 4L), the diagnosis
was established in biopsy of other lymph node stations by
either procedure. The other two patients had tuberculosis
(Station 4R) and nonsmall cell cancer (Station 2R and 4R)
respectively diagnosed on surgical biopsy. One further pa-
tient had negative biopsies of lymph node stations 2L, 4L,
and 7. These were confirmed as true negatives on operation.
Nevertheless, surgical excision biopsy of the primary lung
lesion yielded a diagnosis of small cell lung cancer. There-
fore, combined EBUS-TBNA and mediastinoscopy yielded
an accurate result in 63 (63/66; 95%) patients.
Safety
There were no complications observed with EBUS-
TBNA. Among patients who underwent mediastinoscopy,
there were two cases of postoperative wound infection and
three instances of prolonged bleeding. One other patient
required pro-longed ventilation (24 hours). Nevertheless, as
mediastinoscopy was performed before lung resection in a
combined setting, it was difficult to attribute complications
specifically to mediastinoscopy.
DISCUSSION
In patients who have suspected nonsmall cell cancer
with enlarged paratracheal and subcarinal lymph nodes, the
diagnostic yield of real-time EBUS-TBNA was superior to
the yield of cervical mediastinoscopy. The two procedures
were comparable in ability to establish a definitive histologic
diagnosis and in correctly predicting the pathologic N stage
with the trend in favor of EBUS-TBNA. These findings may
be unexpected given that biopsy specimens from mediasti-
noscopy are obtained under direct vision and are considerably
larger than those from the 22-guage EBUS-TBNA needle.
Nevertheless, the limited sensitivity of mediastinoscopy in
prior studies has been largely attributed to metastases in
lymph nodes not accessible by the mediastinoscope.2 Poste-
rior subcarinal nodes are one such lymph node group that is
beyond the reach of mediastinoscopy and this may explain
the improved yield of EBUS-TBNA at station 7 and the
consequent superior overall diagnostic rate. At the paratra-
cheal lymph node stations 2 and 4, the results of EBUS-
TBNA and mediastinoscopy were not significantly different.
The high diagnostic yield of EBUS-TBNA is attributed
to real-time visualization of the needle tract in the ultrasound
plane during biopsy of lymph nodes. EBUS also may prevent
rare complications associated with conventional TBNA such
as inadvertent vascular and mediastinal injury. Cervical me-
diastinoscopy has a relatively higher complication rate with
mortality reported between 0.08 and 0.2% and a morbidity
rate of 2% and 2.5%.2,17,18 Often reported complications
include arrthymias, bleeding, and injury to adjacent structures
such as the trachea, esophagus, and recurrent laryngeal
nerve.17,18 EBUS is also an outpatient procedure that can be
performed under moderate sedation. Prior data suggest no
difference in the diagnostic rate between EBUS performed
under general anesthesia and under moderate sedation.12
EBUS-TBNA can be easily repeated without the tech-
nical difficulties and increased complication rates encoun-
tered with repeat mediastinoscopy.19 Furthermore, EBUS
has access to N1 lymph node stations beyond the reach of
mediastinoscopy and can also be combined with transesoph-
ageal ultrasound to sample the aortopulmonary (station 5),
paraesophageal (station 8), and inferior pulmonary ligament
(station 9) nodes to accomplish complete endoscopic staging
of the mediastinum.6,20
Although our findings have suggested the role of
EBUS-TBNA as the preferred procedure in diagnosing en-
larged paratracheal and subcarinal lymph nodes in suspected
nonsmall cell lung cancer, mediastinoscopy clearly retains an
important role. The role of invasive staging in a radiologi-
cally normal mediastinum remains controversial and in our
study mediastinoscopy was used to exclude contra lateral
lymph node metastases before proceeding with operation.21
Although there is emerging data on the utility of EBUS-
TBNA in the staging of such nonenlarged mediastinal lymph
nodes, no study with direct comparison against mediastinos-
copy has been performed yet.14 Mediastinoscopy also pro-
vides the surgeon with important preoperative data such as
evidence of lymph node extracapsular extension and medias-
tinal invasion of tumor.22 The utility of EBUS-TBNA outside
the scope of suspected nonsmall cell lung cancer is also
increasing. Recent data in patients with a high clinical sus-
picion of sarcoidosis has shown a diagnostic yield of 85–86%
with EBUS-TBNA.15,23 Nevertheless, more data is needed
with direct comparisons against mediastinoscopy before neg-
ative EBUS-TBNA results can be trusted in patients where
the pretest probability of nonsmall cell lung cancer is low.
The increasing evidence of the accuracy of EBUS-TBNA
in diagnosing mediastinal adenopathy with suspected lung
cancer has paved the way forward for greater collaboration
between the endoscopist and the thoracic surgeon. EBUS-
TBNA is less invasive, safer, and possibly more accurate. It
can be considered a first line procedure when diagnosis and
staging proceed in parallel for patients with a clinically pre-
sumed diagnosis of nonsmall cell lung cancer who also have
radiologic evidence of mediastinal adenopathy. Attempting to
confirm negative EBUS-TBNA findings with mediastinoscopy
should be reconsidered because there is limited additional yield
in combining EBUS-TBNA with mediastinoscopy. Neverthe-
less, in patients with surgically resectable tumors, there remains
a role for preoperative mediastinoscopy to assess local medias-
tinal invasion and to exclude metastases in nonenlarged lymph
nodes. This collaborative paradigm will potentially achieve a
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less invasive and more satisfying histologic staging of the
mediastinum in lung cancer.
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